This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Breast Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

AIM OF STUDY Primary Efficacy Variable: The primary study objective is the proof of efficacy, measured by progression free survival (PFS) in the treatment of metastatic or locally inoperable recurrent breast cancer. Progression-free survival (PFS) is defined as the time from randomisation to disease progression or death. Secondary Efficacy Variables: - Clinical benefit (CR+PR+SD) - ORR (CR+PR) - Time to progression - Time to next Treatment (TTT) - Overall survival - Safety profile

Provided treatments

  • Drug: Paclitaxel and Sorafenib
  • Drug: Paclitaxel

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01320111. The sponsor of the trial is Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH and it is looking for 59 volunteers for the current phase.
Official trial title:
Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer